ResApp (ASX:RAP) share price rockets 11% on new Johnson & Johnson deal

It's been a good day for the digital health company's shares…

| More on:
Jumbo Interactive staffers shaking hands around table agreeing to an acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is soaring during early afternoon trade on Thursday. This comes after the digital health company announced a licensing agreement with global pharmaceutical company, Johnson & Johnson.

At the time of writing, ResApp shares are up 11.32% to 5.9 cents a pop, having earlier jumped to 6.5 cents.

ResApp licenses ResAppDx technology

Investors are driving up the ResApp share price following the company's latest update.

According to its release, ResApp has secured a three-year, non-exclusive licensing agreement with Janssen Pharmaceutica NV. The latter is one of the Janssen pharmaceutical companies of Johnson & Johnson.

The deal will see ResApp provide its ResAppDx technology to Janssen in a respiratory syncytial virus (RSV) clinical trial.

ResAppDx is a smartphone-based acute respiratory diagnostic test that has been developed to diagnose a range of health issues. 

The technology will be used to assess respiratory symptoms of a group of patients with a range of respiratory diseases.

Typically mild and similar to the common cold, RSV symptoms in severe cases can spread to the lower respiratory tract. This causes pneumonia or acute exacerbations of chronic obstructive pulmonary disease (COPD) or asthma.

The trial will run across a number of continents including the United States, Europe, South America, and Asia-Pacific.

Janssen will pay for the development and maintenance costs as well as a fee for each ResAppDx test. The clinical trial is expected to commence later this calendar year.

Commenting on the announcement driving the ResApp share price, CEO and managing director Dr Tony Keating said:

Almost 160,000 people die each year worldwide as a consequence of RSV. ResApp Health is proud to be supporting Janssen in further understanding the impact of this disease on individual patients, which may help to inform prevention and treatment strategies.

With this agreement, we are demonstrating that leading global pharmaceutical companies see the value of ResAppDx in a clinical trial setting. While not expected to have a material impact on our operating results at this stage, this contract represents the beginning of our commercial relationship with Janssen and will further build the body of high quality, clinical evidence regarding the use of ResAppDx.

ResApp share price snapshot

Despite today's positive announcement, ResApp shares have failed to take off in 2021, down around 30%. When looking over the past 12 months, the company's shares have fallen more than 34%.

ResApp presides a market capitalisation of roughly $45.5 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »